Kymera Results Presentation Deck
Kymera is a leader in
Targeted Protein
Degradation (TPD)
Building a fully-integrated,
global biotech company
Initial focus in Immunology/
Inflammation and Oncology,
but already a disease-
agnostic platform
Accelerating forward
integration through key
strategic partnerships
KYMERA ©2022 KYMERA THERAPEUTICS, INC.
Introduction to Kymera
Key accomplishments to date:
Since 2016 founding, advanced 4 clinical stage programs and
developed a deep pipeline positioned to deliver ≥1 IND/year
●
●
●
●
Unique target selection strategy based on using TPD to unlock
high value, undrugged targets
First to advance degraders (KT-474) in healthy volunteers and
patients with HS and AD, demonstrating degrader vs. small
molecule inhibitors (SMI) biological differentiation, and potential
best in class profile in I/I
Demonstrated fidelity of translation of PK, PD and safety across
three clinical programs in I/I and oncology patients
• Well capitalized with $596 million of cash as of 9/30/22
positioning Kymera to accelerate and expand clinical impact in
areas with large clinical and commercial opportunities
PAGE 4View entire presentation